Fate Therapeutics
(NASDAQ) FATE
Fate Therapeutics Financials at a Glance
Market Cap
$141.84M
Revenue (TTM)
$6.65M
Net Income (TTM)
$136.31M
EPS (TTM)
$-1.15
P/E Ratio
-1.06
Dividend
$0.00
Beta (Volatility)
1.59 (High)
Dividend
$0.00
Beta (Volatility)
1.59 (High)
Price
$1.25
Volume
753,934.925
Open
$1.20
Price
$1.25
Volume
753,934.925
Open
$1.20
Previous Close
$1.22
Daily Range
$1.20 - $1.31
52-Week Range
$0.66 - $1.94
Dividend
$0.00
Beta (Volatility)
1.59 (High)
Price
$1.25
Volume
753,934.925
Open
$1.20
Previous Close
$1.22
Daily Range
$1.20 - $1.31
52-Week Range
$0.66 - $1.94
FATE News
FATE: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Fate Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
161
CEO
Bahram Valamehr, PhD, MBA
Website
www.fatetherapeutics.comHeadquarters
San Diego, CA 92131, US
FATE Financials
Key Financial Metrics (TTM)
Gross Margin
-94%
Operating Margin
-22%
Net Income Margin
-21%
Return on Equity
-52%
Return on Capital
-52%
Return on Assets
-43%
Earnings Yield
-94.34%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$141.84M
Shares Outstanding
116.26M
Volume
753.93K
Short Interest
0.00%
Avg. Volume
1.66M
Financials (TTM)
Gross Profit
$6.25M
Operating Income
$147.70M
EBITDA
$127.02M
Operating Cash Flow
$106.08M
Capital Expenditure
$5.95M
Free Cash Flow
$112.04M
Cash & ST Invst.
$203.66M
Total Debt
$77.85M
Fate Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$1.37M
-26.4%
Gross Profit
$11.53M
-720.0%
Gross Margin
-8.42%
N/A
Market Cap
$141.84M
N/A
Market Cap/Employee
$783.65K
N/A
Employees
181
N/A
Net Income
$32.37M
+37.9%
EBITDA
$42.21M
-0.0%
Quarterly Fundamentals
Net Cash
$125.81M
-35.1%
Accounts Receivable
$916.00K
-74.1%
Inventory
$0.00
N/A
Long Term Debt
$73.29M
-5.9%
Short Term Debt
$4.56M
-38.5%
Return on Assets
-42.74%
N/A
Return on Invested Capital
-52.22%
N/A
Free Cash Flow
$24.51M
+12.2%
Operating Cash Flow
$23.31M
+16.1%